Cart (0)

CD39 Inhibitors

CD39 inhibitors represent a class of chemical compounds that target the enzyme CD39, also known as ectonucleoside triphosphate diphosphohydrolase-1 (ENTPD1). CD39 is a membrane-bound enzyme predominantly involved in the hydrolysis of extracellular nucleotides, particularly ATP and ADP, into AMP. The enzyme plays a critical role in the regulation of purinergic signaling by modulating the levels of extracellular nucleotides, which are essential mediators in a variety of physiological processes, including inflammation, immune response, and hemostasis. By inhibiting CD39, these compounds effectively alter the balance of extracellular nucleotides, leading to increased concentrations of ATP and ADP in the extracellular space. This shift in nucleotide levels can have significant effects on cellular signaling pathways, particularly those involving P2 receptors, which are activated by ATP and ADP. These receptors are widely expressed across various tissues and are implicated in numerous cellular functions. The structural diversity of CD39 inhibitors reflects the complexity of the enzyme's active site and its interactions with substrates. Many CD39 inhibitors are designed to mimic the structure of natural nucleotides or their analogs, allowing them to competitively bind to the enzyme's active site. This binding prevents the hydrolysis of ATP and ADP, thus sustaining their extracellular concentrations. Additionally, some inhibitors may interact with allosteric sites on CD39, inducing conformational changes that reduce the enzyme's catalytic efficiency. The development and optimization of CD39 inhibitors often involve detailed studies of the enzyme's structure, including crystallography and computational modeling, to identify key interaction points and to enhance the specificity and potency of these compounds. Moreover, the effects of these inhibitors on CD39 activity are typically assessed through biochemical assays that measure the hydrolysis rates of nucleotides in the presence and absence of the inhibitor, providing insight into the compound's efficacy and mechanism of action.

Product Name	CAS #	Catalog #	QUANTITY	Price	Citations	RATING
ARL 67156 trisodium salt	160928-38-1	sc-203521	5 mg	$311.00	7	(2)
ARL 67156 trisodium salt acts as a potent inhibitor of CD39, a key enzyme in purinergic signaling. Its unique structure facilitates strong binding interactions with the enzyme's active site, effectively blocking ATP hydrolysis. This compound exhibits a high affinity for CD39, leading to altered reaction kinetics and modulation of extracellular nucleotide levels. Its distinct physicochemical properties enhance its stability in various conditions, making it a valuable tool for probing purinergic pathways.
PSB 069	78510-31-3	sc-204216 sc-204216A	5 mg 10 mg	$176.00 $728.00	1	(0)
PSB 069 is a selective inhibitor of CD39, characterized by its ability to disrupt the enzyme's catalytic activity through specific molecular interactions. It engages with the active site, preventing the conversion of ATP to adenosine, thereby influencing purinergic signaling dynamics. The compound's unique steric configuration enhances its binding affinity, resulting in altered reaction kinetics. Additionally, its robust stability under diverse conditions allows for effective exploration of nucleotide metabolism pathways.
Suramin sodium	129-46-4	sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E	50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g	$152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00	5	(1)
Suramin is a polyanionic compound known to inhibit various ATPases and ectonucleotidases, including CD39. Its broad-spectrum inhibitory activity makes Suramin a useful tool to explore the effects of inhibiting multiple enzymes involved in purinergic signaling.
NF 279	202983-32-2	sc-202730	10 mg	$576.00		(0)
NF 279 is a potent and selective P2X receptor antagonist. By blocking P2X receptors, NF 279 indirectly impacts purinergic signaling pathways, including those involving CD39.
8-Bromo-cADP-Ribose (8-Br-cADPR)	151898-26-9	sc-201514 sc-201514B	100 µg 1 mg	$133.00 $561.00	12	(1)
8-Br-cADPR is an analog of cyclic ADP-ribose, a molecule involved in calcium signaling. By modulating calcium dynamics, 8-Br-cADPR can indirectly affect CD39 activity and purinergic signaling.
Zinc	7440-66-6	sc-213177	100 g	$48.00		(0)
Zinc chloride is a compound known to inhibit CD39 enzymatic activity. Through the modulation of CD39, zinc chloride can impact purinergic signaling pathways and extracellular nucleotide levels.
5,5′-Dithio-bis-(2-nitrobenzoic Acid)	69-78-3	sc-359842	5 g	$80.00	3	(3)
5,5′-Dithio-bis-(2-nitrobenzoic Acid) (DTNB) is a thiol-reactive compound that can indirectly modulate CD39 activity by influencing the redox state of the extracellular environment. By altering thiol groups, DTNB may impact the function of CD39 and its role in purinergic signaling.
MRS 1754	264622-58-4	sc-301174 sc-301174A	5 mg 25 mg	$210.00 $818.00	1	(0)
MRS 1754 is a selective antagonist of the P2Y1 receptor, a G protein-coupled receptor involved in purinergic signaling pathways. By blocking P2Y1 receptor activation, MRS 1754 indirectly influences extracellular ATP levels regulated by CD39. R

Santa Cruz Animal Health is a leading provider of animal health care products. ©2026 Santa Cruz Biotechnology Inc. All Rights Reserved.
Toll-Free: 1-800-457-3801 - Terms & Conditions | Privacy Policy | Legal
“Santa Cruz Animal Health”, “San Juan Ranch”, the San Juan Ranch logo, “UltraCruz”, “Supplement of Champions”, are registered trademarks of Santa Cruz Biotechnology, Inc. All other trademarks are the property of their respective owners.

CD39 Inhibitors

ARL 67156 trisodium salt

PSB 069

Suramin sodium

NF 279

8-Bromo-cADP-Ribose (8-Br-cADPR)

Zinc

5,5′-Dithio-bis-(2-nitrobenzoic Acid)

MRS 1754